Prevalence of psoriatic arthritis and comorbidities in patients with severe psoriasis: Data of a retrospective analysis of a hospital cohort
https://doi.org/10.14412/1996-7012-2017-1-19-22
Abstract
Objective: to study the prevalence of psoriatic arthritis (PsA) and comorbidities in a hospital cohort of patients with severe psoriasis (PsO).
Patients and methods. Case history data were retrospectively analyzed in 592 patients with PsO (348 men and 244 women; mean age, 49.2±0.6 years; mean PsO duration, 11.8±0.6 years; mean Psoriasis Area and Severity Index (PASI), 49.4±0.5 scores) who had been treated at the Branch of the V.G. Korolenko Clinic, Moscow Research and Practical Center of Dermatovenereology and Cosmetology, in 2010 to 2011. The diagnosis of comorbidities was confirmed by medical specialists in accordance with the ICD-10 code; the rate and pattern (%) of comorbidities were analyzed.
Results. Out of the 592 patients with PsO, 503 (85.1%) were found to have comorbidities. Diseases of the cardiovascular system (CVS)
(I00–I199) were recorded in the majority (61.6%) of the patients. PsA (L40.5, M07.0–M07.3) was detected in 39.4% of the examinees. Other diseases of the skeletomuscular system unassociated with psoriasis (M00–M99) were present in 27.6% of the patients. Diseases of the gastrointestinal tract (GIT) and hepatobiliary system (K00–K93, B15–B19) were found in 47.5% of the patients. Endocrine diseases, nutritional and metabolic disorders (E00–E90), particularly diabetes mellitus, thyroid diseases, and obesity, were diagnosed in 12.2, 24, and 88% of the patients with PsO, respectively. 13.9% of the patients with PsO had urinary tract diseases, among them there was chronic pyelonephritis (N20), kidney cysts (N28.1), urolithiasis (Q61), prostate diseases (N11) in 73, 71, 47, and 27% of cases, respectively.
Conclusion. Most patients with severe PsO were observed to have comorbidity, primarily diseases of the locomotor apparatus, CVS, and GIT. PsA was recorded in more than one third of patients. Comorbidity was identified in 36% of the patients with PsO.
About the Authors
N. V. Batkaeva
RUDN University
Russian Federation
Russian Federation
Faculty for Advanced Training of Medical Workers
21, Miklukho-Maklai St., Build. 3, Moscow 117198
T. V. Korotaeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
E. A. Batkaev
RUDN University
Russian Federation
Russian Federation
Faculty for Advanced Training of Medical Workers
21, Miklukho-Maklai St., Build. 3, Moscow 117198
References
1. Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol. 2013 Oct;149(10):1173-9. doi: 10.1001/jamadermatol.2013.5015.
2. Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Treatment Recommendations for Psoriatic Arthritis 2015. Arthritis Rheumatol. 2016 May;68(5):1060-71. doi: 10.1002/art.39573. Epub 2016 Mar 23.
3. Бакулев АЛ, Насонов ЕЛ, Коротаева ТВ. Федеральные клинические рекомендации по ведению больных псориатическим артритом. Москва; 2013. 37 с. [Bakulev AL, Nasonov EL, Korotaeva TV. Federal'nye klinicheskie rekomendatsii po vedeniyu bol'nykh psoriaticheskim artritom [Federal clinical practice guidelines for the management of patients with psoriatic arthritis]. Moscow; 2013. 37 p.]
4. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013 Jan;149(1):84-91. doi: 10.1001/2013.jamadermatol.406.
5. Roubille C, Richer V, Starnino T, et al. Evidencebased Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative. J Rheumatol. 2015 Oct;42(10):1767-80. doi: 10.3899/jrheum.141112. Epub 2015 Jul 15.
6. Horreau C, Pouplard C, Brenaut E. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013 Aug;27 Suppl 3:12-29. doi: 10.1111/jdv.12163.
7. Wang Y, Gao H, Loyd CM, et al. Chronic skinspecific inflammation promotes vascular inflammation and thrombosis. J Invest Dermatol. 2012 Aug; 132(8):2067-75. doi: 10.1038/jid.2012.112. Epub 2012 May 10.
8. Wenk KS, Arrington KC, Ehrlich A. Psoriasis and non-alcoholic fatty liver disease. J Eur Acad Dermatol Venereol. 2011 Apr;25(4):383-91. doi: 10.1111/j.1468-3083.2010.03841.x. Epub 2010 Sep 14.
9. Mufaddel A, Abdelghani AE. Psychiatric Comorbidity in Patients with Psoriasis, Vitiligo, Acne, Eczema and Group of Patients with Miscellaneous Dermatological Diagnoses. Open J Psychiatry. 2014;(4):168-75.
10. Oliveira MFSP, Rocha BO, Duarte GV. Psoriasis: Classical and emerging comorbidities. Bras Dermatol. 2015;90(1):9-20. doi: 10.1590/abd1806-4841.20153038.
11. Gladman DD, Chandran V. Observational cohort studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program. Rheumatology (Oxford). 2011 Jan;50(1):25-31. doi: 10.1093/rheumatology/keq262. Epub 2010 Aug 6.
12. Armstrong AW. Do TNF inhibitors reduce the risk of myocardial infarction in psoriasis patients? JAMA. 2013 May 15;309(19):2043-4. doi: 10.1001/jama.2013.4695.
13. Халед Я, Абдель К. Коморбидность псориаза и глютеновой энтеропатии. Крымский терапевтический журнал. 2015;(1):69-73. [Khaled Ya, Abdel' K. Comorbidity of psoriasis and glutenic enteropathy. Krymskii terapevticheskii zhurnal. 2015;(1):69-73. (In Russ.)].
14. Dogan S, Atakan N. Psoriasis: A Disease of Systemic Inflammation with Comorbidities. In: Lima H, editor. Psoriasis – Types, Causes and Medication. InTech; 2013. http://www.intechopen.com/books/psoriasis-types-causes-and-medication/psoriasis-a- disease-of-systemic-inflammationwith-comorbidities
15. Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006 Dec;298(7):321-8. Epub 2006 Sep 22.
16. Mehta NN, Azfar RS, Gelfand JM, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010 Apr;31(8):1000-6. doi: 10.1093/eurheartj/ehp567. Epub 2009 Dec 27.
17. Feldman SR, Zhao Y, Shi L, Tran MH. Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis. J Manag Care Spec Pharm. 2015 Oct;21(10):874-88.
18. Augustin M, Radtke MA, Glaeske G, et al. Epidemiology and Comorbidity in Children with Psoriasis and Atopic Eczema. Dermatology. 2015;231(1):35-40. doi: 10.1159/000381913. Epub 2015 May 8.
19. Reich K, Krü ger K, Mö ssner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaquetype psoriasis. Br J Dermatol. 2009 May;160(5): 1040-7. doi: 10.1111/j.1365-2133.2008.09023.x. Epub 2009 Feb 4.
20. Чамурлиева МН, Логинова ЕЮ, Коротаева ТВ и др. Поражение костно-суставного аппарата у больных псориазом по данным скринингового опросника PEST (Psoriasis Epydemiology Screening Tool) и ревматологического клинико-инструментального обследования. Научно-практическая ревматология. 2014;52(6):636-42. [Chamurlieva MN, Loginova EYu, Korotaeva TV, et al. Osteoarticular injury in psoriatic patients according to the data of PEST (Psoriasis Epidemiology Screening Tool) questionnaire and rheumatological clinicoinstrumental examination. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(6):636-42. (In Russ.)]. doi: 10.14412/1995-4484-2014-636-642.
Review
Views: 812
Email this article 